Vise Technologies Inc. Takes Position in Amicus Therapeutics, Inc. $FOLD

Vise Technologies Inc. acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 32,689 shares of the biopharmaceutical company’s stock, valued at approximately $187,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Nuveen LLC purchased a new stake in shares of Amicus Therapeutics in the first quarter valued at $28,741,000. Assenagon Asset Management S.A. raised its position in Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock valued at $20,249,000 after buying an additional 3,057,072 shares during the period. Millennium Management LLC raised its position in Amicus Therapeutics by 635.1% during the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock valued at $27,413,000 after buying an additional 2,902,375 shares during the period. Redmile Group LLC lifted its stake in Amicus Therapeutics by 35.1% in the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after acquiring an additional 2,478,779 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Amicus Therapeutics by 133.9% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,839,249 shares of the biopharmaceutical company’s stock worth $10,539,000 after acquiring an additional 1,053,015 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on FOLD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Thursday, November 13th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. The Goldman Sachs Group upped their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.57.

Insider Buying and Selling

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total transaction of $243,864.93. Following the transaction, the insider directly owned 322,618 shares in the company, valued at $3,068,097.18. This trade represents a 7.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $9.59 on Wednesday. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The firm has a market cap of $2.96 billion, a PE ratio of -79.91 and a beta of 0.66. The firm’s 50 day moving average price is $8.51 and its 200 day moving average price is $7.19. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $10.35.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The company had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. Amicus Therapeutics’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, research analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.